Multiple patented drugs have expired multinational pharmaceutical companies to step up the Nuggets emerging market
Release time: 2011-04-12 & nbsp & nbsp & nbsp Source:
Business Club, April 12th "The collective expiration of patented drugs，and R & D costs gradually increase、Under the increasingly stringent background of the approval of new drugs，Pharmaceutical crocodiles all over the new pharmaceutical market，with a view to make up for some patented drugs to lose the profit loss of the market after losing the market，and bite off the cream on the new cake on the emerging market by the way。"Yang Weiqiang, who has served as high -level management in many multinational pharmaceutical companies, was interviewed when he was interviewed by reporters，Vividly depicts the new actions of multinational pharmaceutical companies in recent days。
Pfizer announced on April 5th，It will sell its capsule manufacturing company for $ 2.38 billion，Simultaneous reduction of the expected profitability of this year and next year。On the same day，Bolinger Yinghan said，Investment equivalent to 24%of the sales of the prescription drug business invested in the research and development field。A few days before，Bayer Pharmaceutical relocated the global phenomenon business headquarters from Germany to Beijing。The reporter learned，There is a common demand behind these measures: hopes to dig a new "profit pool" in the emerging pharmaceutical market。So，How to grasp the sustainable development of this critical period into the real proposition of these companies。
Supply Chain "Sink"
In the global Stake Sports Bettingstake betting apppharmaceutical industry，The rivers and lakes of multinational pharmaceutical companies have never lack of new stories。
Same in April 5，Merhadon has issued an offer for acquisition of ophthalmology developers ISPH，It is estimated that the total value of the transaction will reach US $ 430 million。It is reported，The purpose of the acquisition of the above company is to expand the share of its ophthalmidic drug business in emerging markets。Compared with，Bollinger Yin Ge looks more urgent，Because the patent expires will bring about 1.4 billion euros in sales losses，Increase investment and development of emerging markets，Especially China、Brazil and Russia Market，It has important strategic significance。
In addition，Bayer also launched a new strategy of regional structure in China，Formed Beijing、Shanghai and Chengdu three major regional centers，Plan for cardiovascular、Diabetes such as chronic diseases such as diabetes sink to the grassroots。
These incidents are not just coincidences。Director Liu, the director of the China Division of a multinational pharmaceutical company, told reporters: "Say to emerging markets，Everyone has a consensus in the past few years。For example, Pfizer authorized India Nicholas to produce hundreds of products，and give Aurobindo 60 drugs in the sales right of more than 70 emerging markets; and in China，The work of Lilly Lilly Strategic Investment Diabetes R & D Center has been started，Provide support for entering the grassroots market in China。and a few months ago，Sanofian Wande acquired the US -China Sun Stone for $ 520 million，officially extended the tentacles to third -tier cities and vast rural markets，The deep meaning lies in actual needs。Also because of this，OEM and CRO are changing the production and operation model of the pharmaceutical industry in emerging markets。”
But，There is another mystery behind this multi -rivers and lakes。
Yang Weiqiang said，"Global competition brings the re -division of labor in the Stake Sports Bettingstake betting apppharmaceutical industry，Currently saving cost、Diversified risks and improvement efficiency are the actual confusion of the continuous development of these big brothers。but，Pay the way to the upcoming patented medicine to the patented medicine，stake sports betting appThey Stake Sports Bettingdeliberately distinguishes the characteristics of the conventional drug market。”
The reporter learned，2010，Bayer Company in Asia Pacific、Latin America、Africa and the Middle East business has expanded sharply。On the contrary，European and American sales have declined。Not only Bayer。According to IMS data,，In recent years，The top 10 pharmaceutical companies in the world have a 6%to 8%decline in the European and American markets.，In the next 5 years，Its market share will be reduced from 38%to 35%，The share of 17 emerging markets including China increased from 7%to 12%。
Analysis of the expansion path of multinational pharmaceutical companies is not difficult to see，"Bomb Bomb" expires、Non -patented drug listing varieties increase、Increased influence and other factors of the payment party tighten their nerves。For this，Yu Xiong, deputy dean of the China Medical Industry Research Institute, asserted at the last National Pharmaceutical Fair: "Facing a patented cliff，Variety of multinational enterprises is very stressful，For example, there are 8 products that GSK lost patent protection from 2009 to 2012，37.7%of its patented products，There are only 6 of those who have patent protection since then，11.5%。In order to alleviate the pressure of profit decline，The development of emerging markets must be strengthened。”
For this status quo，Xu Ming, director of the General Department of the China Medical Protection Chamber of Commerce, believes: "The current transnational pharmaceutical company is undergoing the test of sustainable development。In this context，The low -cost production of emerging markets and the high -end business of mature markets will form a strong fusion impulse。”
"Blue Ocean" flushed
According to IMS data,，Emerging Drug Market is expected to increase by 15%to 17%in 2011，Market size is expected to reach 180 billion US dollars，And before 2014，Nearly 250 billion US dollars of patented patented drugs lost protection，and 2013，Emerging market's dedication to the growth of global drug sales is expected to reach 48%。Experts think，A new "Pharmaceutical City Blue Ocean" has formed。
And all of these transnational pharmaceutical companies that have been sensitive to smell。Sanofi has made huge sums of money in China since 2009、Cardiovascular stake sports betting appstake online sports bettingdrugs、Influenza vaccine production base，At the same time，Acquisitions in Brazil's Medley and Mexico's Kendrick，Therefore, this French pharmaceutical giant becomes a leader in China and the Latin American market。
Similar to this，Pfizer acquired Wyeth after $ 68 billion，Established an emerging market department，As part of its emerging market development strategy and mature product strategy。The same year，GSK cooperate with South Africa Pharmaceutical Company aspen，Enter Africa、Middle East、Asia Pacific and Latin America Market。Not long ago，Novartis acquired Zhejiang Tianyuan, a Chinese vaccine company，The purpose is to strengthen its vaccine combination and product line，Merhado realizes local production through "self -construction+mergers and acquisitions" in China。"Various signs indicate，Transnational pharmaceutical companies are shifting from the original prescription drug sales to strategic layout pharmaceutical industry chain。This aspect is the pressure of the product patent due，On the other hand, it is more likely to prepare for the broad and new low -end market。"Yang Weiqiang said。
For this，Xu Ming will summarize the emerging market of multinational pharmaceutical companies or "two -step strategy"。The first step is to continue to maintain the core advantage of the original medicine，Ensure market share; the second step is to attach importance to the field of generic drugs，Satisfy the Pharmaceutical Pharmaceutical Market; and the new market strategy is grafting resources，Grassing the resource of emerging markets and mature markets，This idea has become clearer in the past two years。
Facts，With the increasing competition in emerging markets，Transnational pharmaceutical companies are trying to achieve differentiation。Yu Xiong said，multinational pharmaceutical companies reflect their respective professionalism。For example, GSK，The strategy is the field of adding analogic drug，Build a imitation medicine、Vaccine、Health products joint defense line，Cut the product research and development line，Study on antidepressant and analgesic drugs stopped，Focus metastasis to the field of neurodegenerative diseases and nerve cell inflammation。Bayer pays more attention to combination My stake betting apptherapy，In China，It has stake sports betting appchosen to invest in mature product diabetes therapy and hypertension drugs for investment。Another strategy is to cultivate the loyalty of local consumers of emerging markets around the product portfolio。”
but，Reporters found that when observing the recent capital increase of multinational pharmaceutical companies，The actions they advance into emerging markets are more cautious。After all, emerging markets are different from mature markets，Its investment returns are unpredictable，Facing the risk of price reduction，Drug prices are relatively low，These are all concerned about transnational pharmaceutical companies。
There is a trend worth noting，It is the research and development pharmaceutical company that starts to enter the field of generic drugs，I hope to expand the market rapidly in the short term，or supplement the product line or enter some new fields。In emerging market，Product、Brand、Market share and sales channels are also valued by them。"China is a member of the emerging market，More research and development capabilities、Management level、High -end learning for hardware facilities and international standards。"Xu Ming believes。(Ma Fei)
Pfizer announced on April 5th，It will sell its capsule manufacturing company for $ 2.38 billion，Simultaneous reduction of the expected profitability of this year and next year。On the same day，Bolinger Yinghan said，Investment equivalent to 24%of the sales of the prescription drug business invested in the research and development field。A few days before，Bayer Pharmaceutical relocated the global phenomenon business headquarters from Germany to Beijing。The reporter learned，There is a common demand behind these measures: hopes to dig a new "profit pool" in the emerging pharmaceutical market。So，How to grasp the sustainable development of this critical period into the real proposition of these companies。
Supply Chain "Sink"
In the global Stake Sports Bettingstake betting apppharmaceutical industry，The rivers and lakes of multinational pharmaceutical companies have never lack of new stories。
Same in April 5，Merhadon has issued an offer for acquisition of ophthalmology developers ISPH，It is estimated that the total value of the transaction will reach US $ 430 million。It is reported，The purpose of the acquisition of the above company is to expand the share of its ophthalmidic drug business in emerging markets。Compared with，Bollinger Yin Ge looks more urgent，Because the patent expires will bring about 1.4 billion euros in sales losses，Increase investment and development of emerging markets，Especially China、Brazil and Russia Market，It has important strategic significance。
In addition，Bayer also launched a new strategy of regional structure in China，Formed Beijing、Shanghai and Chengdu three major regional centers，Plan for cardiovascular、Diabetes such as chronic diseases such as diabetes sink to the grassroots。
These incidents are not just coincidences。Director Liu, the director of the China Division of a multinational pharmaceutical company, told reporters: "Say to emerging markets，Everyone has a consensus in the past few years。For example, Pfizer authorized India Nicholas to produce hundreds of products，and give Aurobindo 60 drugs in the sales right of more than 70 emerging markets; and in China，The work of Lilly Lilly Strategic Investment Diabetes R & D Center has been started，Provide support for entering the grassroots market in China。and a few months ago，Sanofian Wande acquired the US -China Sun Stone for $ 520 million，officially extended the tentacles to third -tier cities and vast rural markets，The deep meaning lies in actual needs。Also because of this，OEM and CRO are changing the production and operation model of the pharmaceutical industry in emerging markets。”
But，There is another mystery behind this multi -rivers and lakes。
Yang Weiqiang said，"Global competition brings the re -division of labor in the Stake Sports Bettingstake betting apppharmaceutical industry，Currently saving cost、Diversified risks and improvement efficiency are the actual confusion of the continuous development of these big brothers。but，Pay the way to the upcoming patented medicine to the patented medicine，stake sports betting appThey Stake Sports Bettingdeliberately distinguishes the characteristics of the conventional drug market。”
The reporter learned，2010，Bayer Company in Asia Pacific、Latin America、Africa and the Middle East business has expanded sharply。On the contrary，European and American sales have declined。Not only Bayer。According to IMS data,，In recent years，The top 10 pharmaceutical companies in the world have a 6%to 8%decline in the European and American markets.，In the next 5 years，Its market share will be reduced from 38%to 35%，The share of 17 emerging markets including China increased from 7%to 12%。
Analysis of the expansion path of multinational pharmaceutical companies is not difficult to see，"Bomb Bomb" expires、Non -patented drug listing varieties increase、Increased influence and other factors of the payment party tighten their nerves。For this，Yu Xiong, deputy dean of the China Medical Industry Research Institute, asserted at the last National Pharmaceutical Fair: "Facing a patented cliff，Variety of multinational enterprises is very stressful，For example, there are 8 products that GSK lost patent protection from 2009 to 2012，37.7%of its patented products，There are only 6 of those who have patent protection since then，11.5%。In order to alleviate the pressure of profit decline，The development of emerging markets must be strengthened。”
For this status quo，Xu Ming, director of the General Department of the China Medical Protection Chamber of Commerce, believes: "The current transnational pharmaceutical company is undergoing the test of sustainable development。In this context，The low -cost production of emerging markets and the high -end business of mature markets will form a strong fusion impulse。”
"Blue Ocean" flushed
According to IMS data,，Emerging Drug Market is expected to increase by 15%to 17%in 2011，Market size is expected to reach 180 billion US dollars，And before 2014，Nearly 250 billion US dollars of patented patented drugs lost protection，and 2013，Emerging market's dedication to the growth of global drug sales is expected to reach 48%。Experts think，A new "Pharmaceutical City Blue Ocean" has formed。
And all of these transnational pharmaceutical companies that have been sensitive to smell。Sanofi has made huge sums of money in China since 2009、Cardiovascular stake sports betting appstake online sports bettingdrugs、Influenza vaccine production base，At the same time，Acquisitions in Brazil's Medley and Mexico's Kendrick，Therefore, this French pharmaceutical giant becomes a leader in China and the Latin American market。
Similar to this，Pfizer acquired Wyeth after $ 68 billion，Established an emerging market department，As part of its emerging market development strategy and mature product strategy。The same year，GSK cooperate with South Africa Pharmaceutical Company aspen，Enter Africa、Middle East、Asia Pacific and Latin America Market。Not long ago，Novartis acquired Zhejiang Tianyuan, a Chinese vaccine company，The purpose is to strengthen its vaccine combination and product line，Merhado realizes local production through "self -construction+mergers and acquisitions" in China。"Various signs indicate，Transnational pharmaceutical companies are shifting from the original prescription drug sales to strategic layout pharmaceutical industry chain。This aspect is the pressure of the product patent due，On the other hand, it is more likely to prepare for the broad and new low -end market。"Yang Weiqiang said。
For this，Xu Ming will summarize the emerging market of multinational pharmaceutical companies or "two -step strategy"。The first step is to continue to maintain the core advantage of the original medicine，Ensure market share; the second step is to attach importance to the field of generic drugs，Satisfy the Pharmaceutical Pharmaceutical Market; and the new market strategy is grafting resources，Grassing the resource of emerging markets and mature markets，This idea has become clearer in the past two years。
Facts，With the increasing competition in emerging markets，Transnational pharmaceutical companies are trying to achieve differentiation。Yu Xiong said，multinational pharmaceutical companies reflect their respective professionalism。For example, GSK，The strategy is the field of adding analogic drug，Build a imitation medicine、Vaccine、Health products joint defense line，Cut the product research and development line，Study on antidepressant and analgesic drugs stopped，Focus metastasis to the field of neurodegenerative diseases and nerve cell inflammation。Bayer pays more attention to combination My stake betting apptherapy，In China，It has stake sports betting appchosen to invest in mature product diabetes therapy and hypertension drugs for investment。Another strategy is to cultivate the loyalty of local consumers of emerging markets around the product portfolio。”
but，Reporters found that when observing the recent capital increase of multinational pharmaceutical companies，The actions they advance into emerging markets are more cautious。After all, emerging markets are different from mature markets，Its investment returns are unpredictable，Facing the risk of price reduction，Drug prices are relatively low，These are all concerned about transnational pharmaceutical companies。
There is a trend worth noting，It is the research and development pharmaceutical company that starts to enter the field of generic drugs，I hope to expand the market rapidly in the short term，or supplement the product line or enter some new fields。In emerging market，Product、Brand、Market share and sales channels are also valued by them。"China is a member of the emerging market，More research and development capabilities、Management level、High -end learning for hardware facilities and international standards。"Xu Ming believes。(Ma Fei)
